Prosecution Insights
Prosecution Insights
8 pending office actions • 6 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (62%) |
| Double-patenting + other | 2 (25%) |
| No statute on record | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAMSELL, RILLA MARIE | 1 | 71.4% | +0.0% |
| SAEED, ALI S | 1 | 30.5% | +34.8% |
| ULLMAN, AARON RAFANAN | 1 | — | — |
| COPPINS, JANET L | 1 | 73.4% | +25.0% |
| ARNOLD, ERNST V | 1 | 48.0% | +12.9% |
| HOWELL, THEODORE R | 1 | 66.8% | +25.4% |
| MAHLUM, JONATHAN DAVIS | 1 | 57.7% | +6.9% |
| MOSS, NATALIE M | 1 | 31.2% | +17.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18273710 | NALTREXONE COMPOSITIONS | ARNOLD, ERNST V | 49d overdue |
| 17435911 | METHOD FOR DETERMINING EFFICACY | MOSS, NATALIE M | 8d overdue |
| 18330163 | ASSAY TO IDENTIFY ANTI-CANCER AGENTS | HOWELL, THEODORE R | 69d |
| 18572637 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | SAEED, ALI S | 76d |
| 18231114 | AUTOIMMUNE THERAPY | COPPINS, JANET L | 83d |
| Art Unit | Apps |
|---|---|
| 1628 | 3 |
| 1624 | 1 |
| 1616 | 1 |
| 1613 | 1 |
| 1625 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18573359 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS | SAMSELL, RILLA MARIE | 1624 | Other | Non-Final OA | 20d | Pending | Dec 21, 2023 |
| 18572637 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | SAEED, ALI S | 1616 | DPOther | Non-Final OA | 76d | Pending | Dec 20, 2023 |
| 18572651 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | ULLMAN, AARON RAFANAN | 1628 | §103 | Non-Final OA | 83d | Pending | Dec 20, 2023 |
| 18231114 | AUTOIMMUNE THERAPY | COPPINS, JANET L | 1628 | §103 | Final Rejection | 83d | Pending | Aug 07, 2023 |
| 18273710 | NALTREXONE COMPOSITIONS | ARNOLD, ERNST V | 1613 | §103 | Final Rejection | 49d overdue | Pending | Jul 21, 2023 |
| 18330163 | ASSAY TO IDENTIFY ANTI-CANCER AGENTS | HOWELL, THEODORE R | 1628 | DPOther | Non-Final OA | 69d | Pending | Jun 06, 2023 |
| 17437724 | CANCER TREATMENT COMPRISING NALTREXONE AND A CANNABINOID | MAHLUM, JONATHAN DAVIS | 1625 | §103 | Final Rejection | 34d | Pending | Sep 09, 2021 |
| 17435911 | METHOD FOR DETERMINING EFFICACY | MOSS, NATALIE M | 1653 | §103 | Final Rejection | 8d overdue | Pending | Sep 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial